Authors:

Ismael Rodriguez Rivera¹, Lin Shen², Shivaani Kummar³, Minal Barve⁴, Caroline Germa⁵, Chuan Qi⁶, Lei chen⁶, Jenny Milata⁵, Jenny Yao⁵, Li Shen⁶, Xuelian Zhu⁶ 

¹NEXT Oncology, San Antonio, TX,²Beijing Cancer Hospital, Beijing, China,³Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, ⁴Mary Crowley Cancer Research Centers, Dallas, TX, ⁵Transcenta Therapeutics Inc., Princeton, NJ,⁶Suzhou Transcenta Therapeutics Co., Ltd, Shanghai, China

Background:

Gremlin-1 (GREM1), a member of the TGF-β superfamily, plays a key role in EMT, and cancer cell proliferation by binding to BMPs. GREM1 is widely expressed in various human cancers and TME stromal cells. Overexpression of GREM1 is correlated with poor prognosis. TST003 is a novel humanized IgG1 monoclonal antibody targeting GREM1 with high affinity and selectivity, and it blocks GREM1 binding to BMP2/4 resulting in enhanced BMP signaling. This study will investigate TST003's safety, tolerability, and preliminary anti-tumor activity in patients with advanced solid tumors.

Study Status:

The enrollment is ongoing in clinical centers in the US and China. No significant safety signals were reported in the first few patients treated with TST003. Clinical trial information: NCT05731271.